NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has received approval from the New York State Department of Health (NYSDOH) to offer Thermo Fisher Scientific's Oncomine Dx Target Test, a next-generation sequencing-based companion diagnostic for three targeted lung cancer treatments.
The 23-gene test can be used to identify best responders to three non-small cell lung cancer treatment regimens: AstraZeneca's EGFR inhibitor Iressa (gefitinib), Pfizer's ALK and ROS1 inhibitor Xalkori (crizotinib), and the combination of Novartis' MEK inhibitor Mekinist (trametinib) and RAF inhibitor Tafinlar (dabrafenib). It received US Food and Drug Administration approval earlier this year.
With the NYSDOH approval, Cancer Genetics is the first and only lab to offer the test in NY state, the company said.
"This approval … marks an important step for the company as we continue to serve a major market with considerable runway for growth as it is projected to reach $3.65 billion over the next six years," Cancer Genetics President and CEO Panna Sharma said in a statement.